Clinical Trial Update: GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of GW572016 (lapatinib) in patients with ErbB2-overexpressing advanced or metastatic breast cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: COMPLETED | Results posted: 2009-12-14